الفهرس 
الغلافOnly 14 pages are availabe for public view
 |  | from | 123 |  |  |
| | | from | 123 | | |
Abstract
Background: Pharmacokinetic clearance models can be important extensions of therapeutic drug monitoring (TDM), as they allow estimation of individual clearance based on patient’s specific demographics, clinical data and measured serum concentrations. These models can be used during dosage adjustment to achieve target steady-state plasma concentrations. The accurate dosage adjustment in patients is needed to avoid possibilities of its ineffectiveness resulting in unnecessary costs or occasionally predisposing patients to a higher risk of toxicity.
Objective: This study explore the utility of routinely collected therapeutic drug monitoring data (1 sample per patient) of carbamazepine and patients specific demographics and clinical data for developing a population pharmacokinetic model for carbamazepine clearance in Egyptian epileptic patients.
Patients and Methods: forty patients of either sex suffering from Epilepsy were selected from the out-patient clinic of the psychiatry hospital of the Armed Forces Medical Center at Maadi; Cairo, Egypt during the period of June 2010 to March 2011 after approval of the hospital medical ethical committee. Patients were selected after full history taking, physical examination and complete investigation. One blood sample for serum determination was drawn from each patient just before next scheduled dose. Carbamazepine serum drug levels were measured by homogenous enzyme immunoassay (The Emit® 2000 Carbamazepine) supplied by Siemens Healthcare Diagnostics Inc., USA. Age, body weight, gender, height, body